PROCEPT BioRobotics (MEX:PRCT) DeferredTaxAndRevenue: MXN247 Mil (As of Mar. 2026)


MEX:PRCT PROCEPT BioRobotics Corp MEX:PRCT
54 GF Score
Price MXN358.45
GF Value MXN1,536.19
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is PROCEPT BioRobotics DeferredTaxAndRevenue?

PROCEPT BioRobotics MEX:PRCT 54 DeferredTaxAndRevenue is MXN247 Mil as of Mar. 2026. GuruFocus rates MEX:PRCT with a GF Score™ of 54/100 and a GF Value™ of MXN1,536.19 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

PROCEPT BioRobotics's current deferred tax and revenue for the quarter that ended in Mar. 2026 was MXN247 Mil.

PROCEPT BioRobotics DeferredTaxAndRevenue Related Terms

PROCEPT BioRobotics DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for PROCEPT BioRobotics's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PROCEPT BioRobotics DeferredTaxAndRevenue Chart

PROCEPT BioRobotics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
DeferredTaxAndRevenue
Get a 7-Day Free Trial 36.23 55.66 96.01 199.49 234.94

PROCEPT BioRobotics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 200.47 186.20 195.64 234.94 247.08
MEX:PRCT
54GF Score
PROCEPT BioRobotics Corp MEX:PRCT
DeferredTaxAndRevenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of MXN247 Mil mean?
PROCEPT BioRobotics (MEX:PRCT) has a DeferredTaxAndRevenue of MXN247 Mil as of Mar. 2026. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on PROCEPT BioRobotics.
Is PROCEPT BioRobotics' DeferredTaxAndRevenue too high?
PROCEPT BioRobotics' current DeferredTaxAndRevenue is MXN247 Mil. Overall, PROCEPT BioRobotics has a GF Score™ of 54/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PROCEPT BioRobotics' DeferredTaxAndRevenue compare to ALMR and AHCO?
PROCEPT BioRobotics' DeferredTaxAndRevenue of MXN247 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Medical Devices & Instruments company?
A good DeferredTaxAndRevenue depends on the Medical Devices & Instruments industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on PROCEPT BioRobotics. PROCEPT BioRobotics's current DeferredTaxAndRevenue is MXN247 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PROCEPT BioRobotics stock overvalued right now?
Based on GuruFocus' analysis, PROCEPT BioRobotics (MEX:PRCT) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN1,536.19, compared to a current price of MXN358.45 — trading 76.7% below its estimated fair value. The current DeferredTaxAndRevenue is MXN247 Mil. PROCEPT BioRobotics' overall GF Score™ is 54/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For PROCEPT BioRobotics (MEX:PRCT), the current DeferredTaxAndRevenue is MXN247 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PROCEPT BioRobotics (MEX:PRCT) Overvalued in 2026?

Based on GuruFocus' analysis, PROCEPT BioRobotics stock appears to be undervalued. The current stock price of MXN358.45 is trading 76.7% below its estimated GF Value™ of MXN1,536.19. GuruFocus considers PROCEPT BioRobotics to be Significantly Undervalued.

Key valuation signals for MEX:PRCT:

  • DeferredTaxAndRevenue: MXN247 Mil
  • GF Value™: MXN1,536.19 vs. price of MXN358.45 (76.7% below fair value)
  • GF Score™: 54/100 with 2 warning signs

No single metric tells the full story. See the MEX:PRCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PROCEPT BioRobotics Business Description

Other Exchanges PRCT:USA
Address 150 Baytech Drive, San Jose, CA, USA, 95134
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
54GF Score

Get the complete analysis for MEX:PRCT

DeferredTaxAndRevenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN358.45
Price
MXN1,536.19
GF Value